Exhaustive French National Registry of AF Ablation Using Pentaspline Pulsed Field Ablation Catheter
NCT ID: NCT06497933
Last Updated: 2024-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
5223 participants
OBSERVATIONAL
2021-03-01
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inflammatory Response Following " Pulsed Field Ablation " vs. Radiofrequency Ablation-2
NCT06160076
Evaluation of the Efficacy of Pulmonary Vein Isolation by Pulsed-field Ablation in Persistent Atrial Fibrillation: a Multicenter Study With Follow-up by Implantable Cardiac Monitor
NCT06985901
The Effect of Pulse Field Ablation on Atrial Mechanics in Catheter Ablation of Paroxysmal Atrial Fibrillation
NCT06557876
Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation
NCT07127900
CLOSE-guided Pulmonary Vein Isolation Using High Power and Stable RF Applications
NCT04122963
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients treated with the Farapulse technology for atrial fibrillation in France from March 2021 to February 29th of 2024 will be included in the registry. The number of participating centers is 33.
A one-year and 2-year follow-up will be performed according to the standard practices of the different centers. The study duration will be 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paroxysmal atrial fibrillation patients
patients with paroxysmal atrial fibrillation undergoing first time catheter ablation using the pentaspline PFA catheter
Atrial fibrillation ablation
Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
Persistent atrial fibrillation patients
patients with persistent atrial fibrillation undergoing first time catheter ablation using the pentaspline PFA catheter
Atrial fibrillation ablation
Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
Long-standing persistent atrial fibrillation patients
patients with long-standing persistent atrial fibrillation undergoing first time catheter ablation using the pentaspline PFA catheter
Atrial fibrillation ablation
Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atrial fibrillation ablation
Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who received catheter ablation for paroxysmal AF, persistent AF, or long-standing persistent AF.
Exclusion Criteria
* Patient's opposition to participating in this registry
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frederic ANSELME, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Rouen
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chaumont C, Laredo M, Thomas O, Maury P, Massoulie G, Defaye P, Boveda S, Marijon E, Escande W, Roux A, Raczka F, Guyomar Y, Jais P, Ollitrault P, Granier M, Fareh S, Marchand H, Pierre B, Abbey S, Noel A, Da Costa A, Extramiana F, Cesari O, Champ-Rigot L, Khoueiry Z, Villemin T, Traulle S, Treguer F, Bader H, Deharo JC, Degand B, Guy-Moyat B, Klug D, Gandjbakhch E, Zhao A, Beneyto M, Eschalier R, Venier S, Combes S, Lepillier A, Mielczarek M, Clementy N, Menet A, Sacher F, De Chillou C, Anselme F. Countrywide introduction of pulsed field ablation for the treatment of atrial fibrillation: Acute results from the FRANCE-PFA registry. Heart Rhythm O2. 2025 Apr 25;6(7):911-919. doi: 10.1016/j.hroo.2025.04.005. eCollection 2025 Jul.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022/0259/OB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.